Close Menu

NEW YORK (GenomeWeb) – Bruker said today that its board of directors has authorized a new share repurchase program under which it may purchase up to $300 million of its common stock over a two-year period beginning May 14, 2019.

The company will fund the repurchases with cash on hand and funds from its existing credit facility. The authorization does not obligate Bruker to purchase any specific number of shares and may be suspended, modified, or terminated at any time, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.